Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

first quarter

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39314

TALKSPACE, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware	84-4636604
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
622 Third Avenue, New York, New York	10017
(Address of principal executive offices)	(Zip Code)

(212) 284-7206

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	TALK	Nasdaq Stock Market
Warrants to purchase common stock	TALKW	Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 6, 2024, the registrant had 169,684,974 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents


		Page
PART I.	FINANCIAL INFORMATION
Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023	3
	Condensed Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2024 and 2023	4
	Condensed Consolidated Statements of Stockholder’s Equity (unaudited) for the three months ended March 31, 2024 and 2023	5
	Condensed Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2024 and 2023	6
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23
PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosures	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
Signatures		26

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

TALKSPACE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	March 31, 2024			December 31, 2023
(U.S. dollars in thousands, except share and per share data)	Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	120,278		$	123,908
Accounts receivable, net		11,035			10,174
Other current assets		4,417			5,718
Total current assets		135,730			139,800
Other long-term assets		2,546			2,421
Total assets	$	138,276		$	142,221
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	5,805		$	6,111
Deferred revenues		2,883			3,069
Accrued expenses and other current liabilities		6,998			12,468
Total current liabilities		15,686			21,648
Warrant liabilities		2,988			1,842
Other long-term liabilities		24			85
Total liabilities		18,698			23,575
Commitments and contingencies (Note 5)
STOCKHOLDERS’ EQUITY:
Common stock of $0.0001 par value — Authorized: 1,000,000,000 shares at March, 2024 (unaudited) and December 31, 2023; Issued and outstanding: 169,569,075 and 168,428,856 shares at March 31, 2024 (unaudited) and December 31, 2023, respectively		16			16
Additional paid-in capital		391,412			389,014
Accumulated deficit		(271,850	)		(270,384	)
Total stockholders’ equity		119,578			118,646
Total liabilities and stockholders’ equity	$	138,276		$	142,221

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

TALKSPACE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


	Three Months Ended
	March 31,
(U.S. dollars in thousands, except share and per share data)	2024			2023
Revenues	$	45,416		$	33,336
Cost of revenues		23,685			16,588
Gross profit		21,731			16,748
Operating expenses:
Research and development		3,739			5,353
Clinical operations, net		1,464			1,601
Sales and marketing		13,009			13,469
General and administrative		5,198			5,364
Total operating expenses		23,410			25,787
Operating loss		(1,679	)		(9,039	)
Financial (income), net		(378	)		(424	)
Loss before taxes on income		(1,301	)		(8,615	)
Taxes on income		165			143
Net loss	$	(1,466	)	$	(8,758	)

Net loss per share:
Basic and Diluted	$	(0.01	)	$	(0.05	)
Weighted average number of common shares used in computing basic and diluted net loss per share:
Basic and Diluted		168,846,946			161,797,781

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

TALKSPACE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY



(U.S. dollars in thousands, except share data)	Common Stock
Three Months Ended March 31, 2024	Number of Shares Outstanding		Amount		Additional paid-in capital			Accumulated deficit			Total
Balance as of December 31, 2023		168,428,856	$	16	$	389,014		$	(270,384	)	$	118,646
Exercise of stock options		605,565	*)			741			—			741
Restricted stock units vested, net of tax		534,654	*)			(595	)		—			(595	)
Stock-based compensation		—		—		2,252			—			2,252
Net loss		—		—		—			(1,466	)		(1,466	)
Balance as of March 31, 2024 (unaudited)		169,569,075	$	16	$	391,412		$	(271,850	)	$	119,578

	Common Stock
Three Months Ended March 31, 2023	Number of Shares Outstanding		Amount		Additional paid-in capital			Accumulated deficit			Total
Balance as of December 31, 2022		161,155,030	$	16	$	378,722		$	(251,202	)	$	127,536
Exercise of stock options		1,739,265	*)			621			—			621
Restricted stock units vested, net of tax		225,050	*)			(65	)		—			(65	)
Stock-based compensation		—		—		2,303			—			2,303
Net loss		—		—		—			(8,758	)		(8,758	)
Balance as of March 31, 2023 (unaudited)		163,119,345	$	16	$	381,581		$	(259,960	)	$	121,637

*) Represents an amount lower than $1

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

TALKSPACE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three Months Ended March 31,
(U.S. dollars in thousands)	2024			2023
Cash flows from operating activities:
Net loss	$	(1,466	)	$	(8,758	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		201			306
Stock-based compensation		2,252			2,303
Remeasurement of warrant liabilities		1,146			189
Increase in accounts receivable		(861	)		(2,820	)
Decrease in other current assets		1,301			559
(Decrease) increase in accounts payable		(306	)		1,213
Decrease in deferred revenues		(186	)		(232	)
Decrease in accrued expenses and other current liabilities		(5,470	)		(6,702	)
Other		(2	)		(95	)
Net cash used in operating activities		(3,391	)		(14,037	)
Cash flows from investing activities:
Purchase of property and equipment		(385	)		(9	)
Proceeds from sale of property and equipment		—			28
Net cash used in investing activities		(385	)		19
Cash flows from financing activities:
Proceeds from exercise of stock options		741			621
Payments for employee taxes withheld related to vested stock-based awards		(595	)		(65	)
Net cash provided by financing activities		146			556
Net decrease in cash and cash equivalents		(3,630	)		(13,462	)
Cash and cash equivalents at the beginning of the period		123,908			138,545
Cash and cash equivalents at the end of the period	$	120,278		$	125,083

Supplemental cash flow data:
Cash paid during the period for income taxes	$	15		$	168

The accompanying notes are an integral part of the condensed consolidated financial statements.

Table of Contents

TALKSPACE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Talkspace, Inc. (together with its consolidated subsidiaries, the “Company” or “Talkspace”) is a leading behavioral healthcare company enabled by a purpose-built technology platform. Talkspace provides individuals and licensed therapists, psychologists and psychiatrists with an online platform for one-on-one therapy delivered via messaging, audio and video. The Company offers convenient and affordable access to a fully credentialed network of highly qualified providers. Since its inception, the Company has connected millions of patients with licensed behavioral health providers across a wide and growing spectrum of care through virtual counseling, psychotherapy, and psychiatry.

The Company's principal executive office is located in New York, NY. The Company's subsidiaries are Talkspace LLC and its wholly-owned subsidiary, Talkspace Network LLC, and Groop Internet Platform LTD. In addition, the Company holds a variable interest in one professional association and eight professional corporations, which have been established pursuant to the requirements of their respective domestic jurisdiction governing the corporate practice of medicine. These entities are considered Variable Interest Entities ("VIEs"). See Note 10, “Variable Interest Entities,” in the notes to the condensed consolidated financial statements for further details.

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2023, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated.

The Company consolidates all subsidiaries in which it has a controlling financial interest, as well as any VIEs where the Company is deemed to be the primary beneficiary. Intercompany transactions and balances have been eliminated in the preparation of the condensed consolidated financial statements.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the recognition and disclosure of revenue recognition, stock-based compensation awards and the fair value of warrant liabilities. The Company bases its estimates on historical factors, current circumstances and the experience and judgment of management. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based on information available at the time they are made. Estimates, by their nature, are based on judgment and available information, therefore, actual results could be materially different from these estimates.

Table of Contents

Recently Issued and Recently Adopted Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023- 07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities

to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.

NOTE 3. REVENUE RECOGNITION

The Company recognizes revenue in accordance with ASC 606, “Revenue from Contracts with Customers”, when the Company satisfies its performance obligation to perform its defined contractual obligations to provide virtual behavioral healthcare services. Revenue is recognized in an amount that reflects the consideration that the Company will be entitled in exchange for the service rendered. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that is included in the transaction price. Variable consideration is included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.

Through its platform, Talkspace serves:

•

Health insurance plans and employee assistance programs (“Payor”) who offer their insured members access to the Company's platform at in-network reimbursement rates,

•

Direct-to-Enterprise customers (“DTE”) who offer their enterprise members access to the Company's platform while their enterprise is under an active contract with Talkspace, and

•

Individual subscribers (“Consumer”) who subscribe directly to the Company's platform.

Payor

The Company contracts with health insurance plans and employee assistance programs to provide therapy and psychiatry services to their eligible covered members. Revenue is recognized at a point in time, as virtual therapy or psychiatry sessions are rendered. The transaction price is determined based on contracted rates and includes variable consideration in the form of implicit price concessions. The Company determines the total transaction price, including an estimate of variable consideration, at contract inception and reassesses this estimate at each reporting date. The Company estimates the amount of variable consideration that is included in the transaction price primarily based on actual historical collection experience for each Payor. Revenue is presented net of implicit price concessions. Payor contracts include annual evergreen clauses and generally may be terminated by either party typically upon a minimum 60-day advance notice.

DTE

The Company contracts with enterprises to provide access to the Company's therapist platform for their enterprise members, primarily based on a per-member-per-month access fee model. To the extent the transaction price includes variable consideration, revenue is recognized using the variable consideration allocation exception, or, if the allocation exception is not met, the Company recognizes revenue ratably based on estimates of the variable consideration to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequent resolved. The majority of DTE contracts typically range in length from one to three years and are generally non-cancelable during the initial contractual term.

Table of Contents

Consumer

The Company also generates revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to the Company's therapy platform as well as supplementary a la carte offerings directly to individual consumers through a subscription plan. The Company recognizes consumer revenues ratably over the subscription period, beginning when therapy services commence. The Company recognizes revenues from supplementary a la carte offerings at a point in time, as virtual therapy sessions are rendered. Members may cancel their subscription at any time and will receive a pro-rata refund for the subscription price. The transaction price from member subscription revenue and supplementary a la carte offerings includes variable consideration in the form of refunds. Revenue is presented net of refunds. The Company estimates the refund liability for the variable consideration portion of the transaction price primarily based on historical experience. The refund liability is recorded within the “Accrued expenses and other current liabilities” line item in the consolidated balance sheets. The refund liability was immaterial as of March 31, 2024 and December 31, 2023.

The following table presents the Company’s revenues from sales to unaffiliated customers disaggregated by revenue source:


	Three Months Ended March 31,
(in thousands)	2024		2023
Revenues from sales to unaffiliated customers:	Unaudited		Unaudited
Payor	$	28,508	$	14,811
DTE		9,913		8,676
Consumer		6,995		9,849
Total revenue	$	45,416	$	33,336

Accounts Receivable and Allowance for Credit Losses

The Company had receivables related to revenue from DTE customers of $8.3 million and $7.8 million at March 31, 2024 and December 31, 2023, respectively. As of March 31, 2024 and December 31, 2023, the balance of receivables related to revenue from Payor customers was $2.7 million and $2.4 million, respectively.

Accounts receivables are stated net of credit losses allowance. The Company’s methodology for estimating credit loss is based on historical collection experience, customer creditworthiness, current and future economic condition and market condition. Additionally, specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. Accounts receivables are written off after all reasonable means to collect the full amount have been exhausted. Credit losses were immaterial for the three months ended March 31, 2024 and 2023.

Deferred Revenue

The Company records deferred revenues when cash payments from customers are received in advance of the Company's performance obligation to provide services. As of March 31, 2024 and December 31, 2023, deferred revenue related mainly to consumer subscriptions. The Company expects to satisfy the majority of its performance obligations associated with deferred revenue within one year or less. Revenue recognized in the three months ended March 31, 2024 and 2023, that was included in the deferred revenue balance at the beginning of each reporting period was immaterial.

NOTE 4. FAIR VALUE MEASUREMENTS

The carrying value of the Company’s cash equivalents, accounts receivable, other current assets, accounts payable, and accrued liabilities approximate fair value because of the relatively short-term nature of the underlying assets or liabilities. Money market funds are classified within Level 1 of the fair value hierarchy because these assets are valued based on quoted market prices in active markets.

The Company's Private Placement Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities in the accompanying consolidated balance sheets. The warrant liabilities were measured at fair value at inception and thereafter on a recurring, quarterly basis, with changes in fair value presented within the statement of operations (financial income, net) line item. The Private Placement Warrants were valued using the Black-Scholes-Merton Model, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the implied volatility from trading prices of the Company's Public Warrants, significant increases (decreases) in this input in isolation would have resulted in a significantly higher (lower) fair value measurement.

Table of Contents

The following were the inputs utilized in determining the fair value of the Private Placement Warrants as of March 31, 2024 and 2023:


	March 31,
Unaudited	2024	2023
Dividend yield (1)	0%	0%
Expected volatility (2)	56.40%	96.20%
Risk-free interest rate (3)	4.55%	3.75%
Term to warrant expiration (years)	2.22	3.23

(1) No dividends were paid during the three months ended March 31, 2024 and 2023.

(2) The expected volatility is based on the back-solved implied volatility of the Company's public warrants as of the valuation date.

(3) The risk-free interest rate is based on the yield from U.S. Treasury bonds with an equivalent term to the time to maturity of the warrants.

Assets and Liabilities Measured at Fair Value

The Company's assets and liabilities recorded at fair value on a recurring basis as of March 31, 2024 and 2023, have been categorized based upon the fair value hierarchy as follows:


	Fair Value Measurements as of March 31, 2024
	Unaudited
(in thousands)	Level 1		Level 2		Level 3		Total
Assets
Cash	$	446	$	—	$	—	$	446
Cash equivalents
Money market funds		119,832		—		—		119,832
Total cash and cash equivalents	$	120,278	$	—	$	—	$	120,278
Liabilities
Private Placement Warrants		—		—		2,988		2,988
Total Warrant Liabilities	$	—	$	—	$	2,988	$	2,988

	Fair Value Measurements as of December 31, 2023
(in thousands)	Level 1		Level 2		Level 3		Total
Assets
Cash	$	1,078	$	—	$	—	$	1,078
Cash equivalents
Money market funds		122,830		—		—		122,830
Total cash and cash equivalents	$	123,908	$	—	$	—	$	123,908
Liabilities
Private Placement Warrants		—		—		1,842		1,842
Total Warrant Liabilities	$	—	$	—	$	1,842	$	1,842

The following table presents changes in Level 3 liabilities measured at fair value on a recurring basis during the three months ended March 31, 2024 and 2023:


	Level 3 Liabilities
			Unaudited
	For the Three Months Ended March 31, 2024
(in thousands)	Beginning Balance		Change in Fair Value		Ending Balance
Private Placement Warrants	$	1,842	$	1,146	$	2,988

	Level 3 Liabilities
			Unaudited
	For the Three Months Ended March 31, 2023
(in thousands)	Beginning Balance		Change in Fair Value		Ending Balance
Private Placement Warrants	$	939	$	189	$	1,128

Table of Contents

NOTE 5. COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

The Company may in the future be involved in various legal proceedings, claims and litigation that arise in the normal course of business. The Company accrues for estimated loss contingencies related to legal matters when available information indicates that it is probable a liability has been incurred and the Company can reasonably estimate the amount of that loss. In many proceedings, however, it is inherently difficult to determine whether any loss is probable or even possible or to estimate the amount of any loss. In addition, even where a loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously recognized loss contingency, it is often not possible to reasonably estimate the size of the possible loss or range of loss or possible additional losses or range of additional losses. As of March 31, 2024, there were no pending material legal proceedings, claims or litigation.

Warranties and Indemnification

The Company’s arrangements generally include certain provisions for indemnifying customers against liabilities if there is a breach of a customer’s data or if the Company’s service infringes a third party’s intellectual property rights. To date, the Company has not incurred any material costs as a result of such indemnifications.

The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by the Company, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer liability insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may also be subject to indemnification obligations by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions.

NOTE 6. CAPITAL STOCK

The Company’s authorized capital stock consists of (a) 1,000,000,000 shares of common stock, par value $0.0001 per share; and (b) 100,000,000 shares of preferred stock, par value $0.0001 per share. As of March 31, 2024 and December 31, 2023 there were outstanding 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock at an exercise price of $11.50 per share. As of March 31, 2024 and December 31, 2023, no shares of preferred stock were issued or outstanding.

On February 22, 2024, the Company announced that its Board of Directors approved a share repurchase program which authorizes the repurchase of up to $15 million of the currently outstanding shares of the Company’s common stock over a period of twenty-four months beginning on March 1, 2024 (the “Repurchase Program”). As of March 31, 2024, no shares have been purchased under the Repurchase Program.

The Company may repurchase shares through various methods, including open market purchases and privately-negotiated transactions, or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 of the Securities Exchange Act of 1934 (the “Exchange Act”). Such purchases will be at times and in amounts as the Company deems appropriate, based on factors such as price, market conditions, corporate and regulatory requirements, constraints specified in any Rule 10b5-1 trading plans, alternative investment opportunities and other business considerations. All shares purchased will be canceled. The Repurchase Program does not obligate the Company to repurchase any dollar amount or number of shares, and may be suspended or terminated at any time.

NOTE 7. SHARE-BASED COMPENSATION

In June 2021, the Company adopted the 2021 Incentive Award Plan (the “2021 Plan”) under which the Company may grant cash and equity incentive awards to officers, employees, directors, consultants and service providers in order to attract, motivate and retain talent. The 2021 Plan replaced the Company's previous stock compensation plan.

All stock-based awards are measured based on the grant date fair value and are generally recognized on a straight-line basis in the Company’s condensed consolidated statement of operations over the requisite service period (generally requiring a four-year vesting period).

Table of Contents

The following table sets forth the total share-based compensation expense related to stock options and restricted stock units included in the respective components of operating expenses in the condensed consolidated statements of operations:


	Three Months Ended March 31,
	2024		2023
(in thousands)	Unaudited		Unaudited
Research and development	$	635	$	674
Clinical operations, net		51		120
Sales and marketing		449		391
General and administrative		1,117		1,118
Total stock-based compensation expense	$	2,252	$	2,303

NOTE 8. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented:


	Three Months Ended March 31,
	2024			2023
(in thousands, except share and per share data)	Unaudited			Unaudited
Net loss	$	(1,466	)	$	(8,758	)
Weighted-average shares used to compute net loss per share:
Basic and Diluted		168,846,946			161,797,781
Net loss per share:
Basic and Diluted	$	(0.01	)	$	(0.05	)

For the three months ended March 31, 2024, the following were excluded from the calculation of diluted net loss per share since each would have had an anti-dilutive effect given the Company's net loss: 10,957,900 vested and non-vested stock options outstanding, 9,650,229 non-vested and outstanding restricted stock units, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock.

For the three months ended March 31, 2023, the following were excluded from the calculation of diluted income per share since each would have had an anti-dilutive effect given the Company's net loss: 14,746,915 vested and non-vested stock options outstanding, 11,549,261 non-vested and outstanding restricted stock units, 12,780,000 Private Placement Warrants and 21,350,000 Public Warrants to purchase the Company’s common stock.

NOTE 9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The following table presents the amounts included within accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023:


	March 31, 2024		December 31, 2023
(in thousands)	Unaudited
Employee compensation	$	2,073	$	7,269
User acquisition		1,831		1,525
Professional fees		743		626
Other		2,351		3,048
Accrued expenses and other current liabilities	$	6,998	$	12,468

Table of Contents

NOTE 10. VARIABLE INTEREST ENTITIES ("VIEs")

The Company holds a variable interest in Talkspace Provider Network, PA (“TPN”) and eight affiliated professional corporations (“PC entities”). The Company evaluates whether an entity in which it has a variable interest is considered a VIE. VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to direct the activities of the entity that most significantly impact the entity's economic performance through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity). TPN and the PC entities are considered VIEs.

Under the provisions of ASC 810, “Consolidation”, an entity consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both (a) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance, and (b) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

The Company has determined that it is able to direct the activities of TPN and the PC entities that most significantly impact their economic performance and it funds and absorbs all losses of these VIEs resulting in the Company being the primary beneficiary of these entities. Accordingly, the Company consolidates these VIEs.

The following table details the assets and liabilities of the VIEs as of March 31, 2024 and December 31, 2023. The assets and liabilities in the table below are presented prior to consolidation and thus a portion of these assets and liabilities are eliminated in consolidation.


	March 31, 2024		December 31, 2023
(in thousands)	Unaudited
ASSETS
Cash and cash equivalents	$	603	$	167
Accounts receivable		7,198		4,031
Other assets		9,797		11,493
Total Assets	$	17,598	$	15,691
LIABILITIES
Accrued expenses and other current liabilities		1,691		2,831
Total Liabilities	$	1,691	$	2,831

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Unless the context otherwise requires, all references in this section as to “Talkspace,” the “Company,” “we,” “us” or “our” refer to the business of Talkspace, Inc. and its consolidated subsidiaries.

The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes contained in this Quarterly Report and the financial statements and related notes contained in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. This discussion contains forward-looking statements that reflect our plans, estimates, and beliefs that involve risks and uncertainties. As a result of many factors, such as those discussed in Part I, Item 1A, “Risk Factors” of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and “Forward-Looking Statements” sections and elsewhere in this Quarterly Report, our actual results may differ materially from those anticipated in these forward-looking statements.

The purpose of this section is to discuss and analyze our consolidated financial condition, liquidity and capital resources and results of operations for the three months ended March 31, 2024 and 2023.

Overview

Talkspace is a healthcare company offering its members convenient and affordable access to a fully-credentialed network of highly qualified providers. We are a leading virtual behavioral health company and, since Talkspace’s founding in 2012, we have connected millions of patients with licensed mental health providers across a wide and growing spectrum of care through virtual counseling, psychotherapy and psychiatry. We created a purpose-built platform to address the vast, unmet and growing demand for mental health services of our members, serving our payor customers (“Payor”), comprised of health plans and employee assistance programs such as Aetna, Cigna, and Optum, who offer their insured members access to our platform at in-network reimbursement rates; our Direct-to-Enterprise customers ("DTE") comprised of enterprises such as Google, the University of Kentucky and the New York City Department of Health and Mental Hygiene, who offer their enterprise members access to our platform while their enterprise is under an active contract with Talkspace; and individual consumers ("Consumer") who subscribe directly to our platform.

As of March 31, 2024, we had approximately 131.4 million eligible lives compared to 98 million eligible lives as of March 31, 2023. As of March 31, 2024, we had over 11,100 consumer active members compared to 15,100 consumer active members as of March 31, 2023. For the three months ended March 31, 2024, our clinicians completed 284,200 sessions related to members covered under our Payor customers, compared to 171,700 completed sessions for the three months ended March 31, 2023. Please refer to the “Key Business Metrics” section below for a description of eligible lives and consumer active members.

Inflation Risk and Economic Conditions

The demand for our solution is dependent on the general economy, which is in turn affected by geopolitical conditions, the stability of the global credit markets, inflationary pressures, increasing interest rates, the industries in which our Payor and DTE customers operate or serve, and other factors. Downturns in the general economy could disproportionately affect the demand for our solution and cause it to decrease.

Our operations could also be impacted by inflation and increased interest rates. Inflation did not have a material effect on our business, financial condition or results of operations for the three months ended March 31, 2024 and 2023. However, if our costs were to become subject to significant inflationary pressures (such as Provider cost), we may not be able to fully offset such higher costs through price increases or cost savings. Our inability or failure to do so could harm our business, financial condition or results of operations.

Operating Segments

The Company operates as a single segment, which is how the chief operating decision maker (who is the chief executive officer) reviews financial performance and allocates resources.

Table of Contents

Key Business Metrics

We monitor the following key metrics to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. We believe the following metrics are useful in evaluating our business:


	Three Months Ended March 31,
	2024	2023
(in thousands except number of health plan and enterprise customers or otherwise indicated)	Unaudited	Unaudited
Number of eligible lives at period end (in millions)	131.4	98.0
Number of completed Payor sessions during the period	284.2	171.7
Unique Payor active members during the period	86.3	61.9
Number of health plan customers at period end	23	20
Number of enterprise customers at period end	195	227
Number of Consumer active members at period end	11.1	15.1

Eligible Lives: We consider eligible lives “eligible” if such persons are eligible to receive treatment on the Talkspace platform, in the case of our Payor customers, at an agreed upon reimbursement rate through insurance under an employee assistance program or other network behavioral health paid benefit program. There may be instances where a person may be covered through multiple solutions, typically through behavioral health plans and employee assistance programs. In these instances, the person is counted each time they are covered in the eligible lives calculation, which may cause this amount to reflect a higher number of eligible lives than we actually serve.

Active Members: We consider consumer members “active” commencing on the date such member initiates contact with a provider on our platform until the term of their monthly, quarterly or bi-annual subscription plan expires, unless terminated early.

Unique Payor Active Members: Represents unique users who had a session completed during the period.

Components of Results of Operations

Revenues

We generate revenues from services provided to individuals who are qualified to receive access to the Company's services through our commercial arrangements with health insurance plans, employee assistance organizations and enterprises. We also generate revenues from the sale of monthly, quarterly, bi-annual and annual membership subscriptions to the Company's therapy platform as well as supplementary a la carte offerings directly to individual consumers through a subscription plan. See Note 3, “Revenue Recognition” in the notes to the condensed consolidated financial statements for further details.

Revenue growth is generated from a combination of increasing our eligible covered lives through contracting with health insurance plans and employee assistance organizations, increasing utilization within eligible covered lives, expanding enterprise customers, and increasing membership subscriptions.

Cost of Revenues

Cost of revenues is comprised primarily of therapist payments. Cost of revenues is largely driven by number of sessions and the size of our provider network that is required to service the growth of our health plan and enterprise customers, in addition to the growth of our customer base.

We designed our business model and our provider network to be scalable and to leverage a hybrid model of both employee providers and independently contracted providers to support multiple growth scenarios. The compensation paid to our independently contracted providers is variable, and the amount paid to a provider is generally based on the amount of time committed by such provider to our members. Our employee providers receive a fixed-salary and discretionary bonuses, where applicable, all of which is included in cost of revenues.

Table of Contents

While we expect to make increased investments to support accelerated growth and the required investment to scale our provider network, we also expect increased efficiencies and economies of scale. Our cost of revenues as a percentage of revenues is expected to fluctuate from period to period depending on the interplay of these factors as well as pricing fluctuations.

Operating Expenses

Operating expenses consist of research and development, clinical operations, sales and marketing, and general and administrative expenses.

Research and Development Expenses

Research and development expenses include personnel and related expenses for software development and engineering, information technology infrastructure, security, privacy compliance and product development (inclusive of stock-based compensation for our research and development employees), third-party services and contractors related to research and development, information technology and software-related costs.

Clinical Operations Expenses

Clinical operations expenses are associated with the management of our network of therapists. This item is comprised of costs related to recruiting, onboarding, credentialing, training and ongoing quality assurance activities (inclusive of stock-based compensation for our clinical operations employees), costs of third-party services and contractors related to recruiting and training and software-related costs.

Sales and Marketing Expenses

Sales expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, travel and stock-based compensation costs for our employees engaged in sales and account management.

Marketing expenses consist primarily of advertising and marketing expenses for member acquisition and engagement, as well as personnel costs, including salaries, benefits, bonuses, stock-based compensation expense for marketing employees, third-party services and contractors. Marketing expenses also include third-party software subscription services, third-party independent research, participation in trade shows, brand messaging and costs of communications materials that are produced for our customers to generate greater awareness and utilization of our platform among our Payor and DTE customers.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel costs, including salaries, benefits, bonuses and stock-based compensation expense for certain executives, finance, accounting, legal and human resources functions, as well as professional fees, occupancy costs, and other general overhead costs.

Financial (income), net

Financial (income), net includes the impact from (i) non-cash changes in the fair value of our warrant liabilities, (ii) interest earned on cash equivalents deposited in our money market accounts and (iii) other financial expenses in connection with bank charges.

Taxes on income

Taxes on income consists primarily of foreign income taxes related to income generated by our subsidiary organized under the laws of Israel. Taxes on income were immaterial for the three months ended March 31, 2024 and 2023.

We have a full valuation allowance for our U.S. deferred tax assets, including federal and state NOLs. We expect to maintain this valuation allowance until it becomes more likely than not that the benefit of our federal and state deferred tax assets will be realized through expected future taxable income in the United States.

Table of Contents

Results of Operations

The following table presents our results of operations for the three months ended March 31, 2024 and 2023 and the dollar and percentage change between the respective periods:


	Three Months Ended March 31,		Variance
(in thousands, except percentages)	2024	2023	$	%
Revenue:	Unaudited	Unaudited
Payor revenue	$28,508	$14,811	13,697	92.5
DTE revenue	9,913	8,676	1,237	14.3
Consumer revenue	6,995	9,849	(2,854)	(29.0)
Total revenue	45,416	33,336	12,080	36.2
Cost of revenue	23,685	16,588	7,097	42.8
Gross profit	21,731	16,748	4,983	29.8
Operating expenses:
Research and development	3,739	5,353	(1,614)	(30.2)
Clinical operations, net	1,464	1,601	(137)	(8.6)
Sales and marketing	13,009	13,469	(460)	(3.4)
General and administrative	5,198	5,364	(166)	(3.1)
Total operating expenses	23,410	25,787	(2,377)	(9.2)
Operating loss	(1,679)	(9,039)	7,360	81.4
Financial (income), net	(378)	(424)	46	(10.8)
Loss before taxes on income	(1,301)	(8,615)	7,314	84.9
Taxes on income	165	143	22	15.4
Net loss	$(1,466)	$(8,758)	$7,292	83.3

Revenues. Revenues increased by $12.1 million, or 36.2% to $45.4 million for the three months ended March 31, 2024 from $33.3 million for the three months ended March 31, 2023. The increase was principally due to a 92.5% increase in Payor revenue driven by a higher number of completed payor sessions, and a 14.3% growth in DTE revenue, partially offset by a 29.0% decline in Consumer revenue. Revenue from our Payor customers increased by $13.7 million, or 92.5%, to $28.5 million for the three months ended March 31, 2024 from $14.8 million for the three months ended March 31, 2023. Revenue from our DTE customers increased by $1.2 million, or 14.3% to $9.9 million for the three months ended March 31, 2024 from $8.7 million for the three months ended March 31, 2023. Consumer revenue decreased by $2.9 million, or 29.0%, to $7.0 million for the three months ended March 31, 2024 from $9.8 million for the three months ended March 31, 2023, due to the Company's intentional and strategic decision to optimize and focus marketing efforts on attracting payor members. While we no longer have marketing resources dedicated solely to the Consumer category, it continues to have a positive contribution to our financial results.

Costs of revenues. Cost of revenues increased by $7.1 million, or 42.8%, to $23.7 million for the three months ended March 31, 2024 from $16.6 million for the three months ended March 31, 2023. The increase in cost of revenues for the three months ended March 31, 2024, was primarily due to increased hours worked by therapists to meet increased member engagement.

Gross profit. Gross profit increased by $5.0 million, or 29.8%, to $21.7 million for the three months ended March 31, 2024 from $16.7 million for the three months ended March 31, 2023. The increase in gross profit was primarily driven by an increase in the Company's revenues.

Gross margin was 47.8% for the three months ended March 31, 2024, compared to 50.2% during the three months ended March 31, 2023. The decline in gross margin was driven by a shift in revenue mix towards Payor.

Operating expenses

Overall, our operating expenses for the three months ended March 31, 2024 have decreased compared to the three months ended March 31, 2023 due to our efforts to achieve greater operational efficiency.

Research and development expenses. Research and development expenses decreased by $1.6 million, or 30.2% to $3.7 million for the three months ended March 31, 2024 from $5.3 million for the three months ended March 31, 2023. The decrease in research and development expenses for the three months ended March 31, 2024 was primarily due to a decrease in employee-related costs, inclusive of non-cash stock compensation expense.

Table of Contents

Clinical operations expenses. Clinical operations expenses decreased by $0.1 million, or 8.6% to $1.5 million for the three months ended March 31, 2024 from $1.6 million for the three months ended March 31, 2023. The decrease in clinical operations expenses for the three months ended March 31, 2024 was primarily due to employee-related costs, inclusive of non-cash stock compensation expense.

Sales and marketing expenses. Sales and marketing expenses decreased by $0.5 million, or 3.4%, to $13.0 million for the three months ended March 31, 2024 from $13.5 million for the three months ended March 31, 2023. The decrease in sales and marketing expenses for the three months ended March 31, 2024 was primarily driven by a decrease in subcontractor costs and direct marketing and promotional costs, partially offset by an increase in employee-related costs, inclusive of non-cash stock compensation expense.

General and administrative expenses. General and administrative expenses decreased by $0.2 million, or 3.1%, to $5.2 million for the three months ended March 31, 2024 from $5.4 million for the three months ended March 31, 2023. The decrease in general and administrative expenses for the three months ended March 31, 2024 was primarily due to a decrease in subcontractor costs, recruitment costs and employee-related costs, inclusive of non-cash stock compensation expense, partially offset by an increase in professional fees.

Financial (income), net. Financial (income), net was $0.4 million for the three months ended March 31, 2024 and 2023. For the three months ended March 31, 2024 and 2023 financial income, net, primarily consisted of interest income earned on our money market accounts of $1.6 million and $0.6 million, respectively, partially offset by $1.1 million and $0.2 million, respectively, in non-cash losses resulting from the remeasurement of warrant liabilities.

Taxes on income. Taxes on income consists primarily of foreign income taxes related to income generated by our subsidiary organized under the laws of Israel. Taxes on income were immaterial for the three months ended March 31, 2024 and 2023.

Non-GAAP Financial Measures

In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance, and our management uses it as a key performance measure to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities. We also use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP.

Some of the limitations of adjusted EBITDA include (i) adjusted EBITDA does not necessarily reflect capital commitments to be paid in the future and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these requirements. In evaluating adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments described herein. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. Our adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as we calculate the measure, limiting its usefulness as a comparative measure. Adjusted EBITDA should not be considered as an alternative to loss before income taxes, net loss, loss per share, or any other performance measures derived in accordance with U.S. GAAP. When evaluating our performance, you should consider adjusted EBITDA alongside other financial performance measures, including our net loss and other GAAP results.

A reconciliation is provided below for adjusted EBITDA to net loss, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our financial statements prepared in accordance with GAAP and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.

Table of Contents

We do not provide a forward-looking reconciliation of adjusted EBITDA guidance as the amount and significance of the reconciling items required to develop meaningful comparable GAAP financial measures cannot be estimated at this time without unreasonable efforts. These reconciling items could be meaningful.

We calculate adjusted EBITDA as net loss income adjusted to exclude (i) depreciation and amortization, (ii) interest and other expenses (income), net, (iii) tax benefit and expense, and (iv) stock-based compensation expense.

The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net loss for the three months ended March 31, 2024 and 2023:


	Three Months Ended March 31,
	2024	2023
(in thousands)	Unaudited	Unaudited
Net loss	$(1,466)	$(8,758)
Add:
Depreciation and amortization	201	306
Financial (income), net (1)	(378)	(424)
Taxes on income	165	143
Stock-based compensation	2,252	2,303
Adjusted EBITDA	$774	$(6,430)

(1)

For the three months ended March 31, 2024, financial (income), net, primarily consisted of $1.6 million of interest income from our money market accounts partially offset by $1.1 million in losses resulting from the remeasurement of warrant liabilities. For the three months ended March 31, 2023, financial (income) net, primarily consisted of $0.6 million of interest income from our money market accounts partially offset by $0.2 million in losses resulting from the remeasurement of warrant liabilities.

Liquidity and Capital Resources

As of March 31, 2024, we had $120.3 million of cash and cash equivalents ($123.9 million as of December 31, 2023), which we use to finance our operations and support a variety of growth initiatives and investments. We had no debt as of March 31, 2024.

Our primary cash needs are to fund operating activities and invest in technology development. Our future capital requirements will depend on many factors including our growth rate, contract renewal activity, the timing and extent of investments to support product development efforts, our expansion of sales and marketing activities, the introduction of new and enhanced service offerings, and the continuing market acceptance of virtual behavioral services. Additionally, we may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies.

We currently anticipate to be able to fund our cash needs for at least the next 12 months and thereafter for the foreseeable future using available cash and cash equivalent balances as of March 31, 2024. However, in the future we may require additional capital to respond to technological advancements, competitive dynamics, customer demands, business and investment opportunities, acquisitions or unforeseen circumstances and we may determine to engage in equity or debt financings for other reasons. We may not be able to timely secure additional debt or equity financing on favorable terms, or at all. If we raise additional funds through the issuance of equity or convertible debt or other equity-linked securities, our existing stockholders could experience significant dilution. Any debt financing obtained by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we cannot raise capital when needed, we may be forced to undertake asset sales or similar measures to ensure adequate liquidity.

Table of Contents

Cash Flows from Operating, Investing and Financing Activities

The following table presents the summary condensed consolidated cash flow information for the periods presented:

Cash Flows


	Three Months Ended March 31,
	2024			2023
(in thousands)	Unaudited			Unaudited
Net cash used in operating activities	$	(3,391	)	$	(14,037	)
Net cash used in investing activities		(385	)		19
Net cash provided by financing activities		146			556
Net decrease in cash and cash equivalents	$	(3,630	)	$	(13,462	)

Operating Activities

The decrease in net cash used in operating activities was primarily driven by a lower net loss, an improvement in collections of receivables and a favorable timing of payments of accrued expenses for the three months ended March 31, 2024 compared to the three months ended March 31, 2023.

Investing Activities

The increase in net cash used in investing activities was driven primarily by an increase in capitalized internal-use software costs which is included within purchase of property and equipment in the condensed consolidated statements of cash flows during the three months ended March 31, 2024 compared to March 31, 2023.

Financing Activities

The decrease in net cash provided by financing activities was driven primarily by an increase in taxes paid related to vested stock-based awards during the three months ended March 31, 2024 compared to March 31, 2023.

Contractual Obligations, Commitments and Contingencies

As of March 31, 2024, we did not have any short-term or long-term debt, or significant long-term liabilities. As of March 31, 2024, we have a non-material long-term operating lease for our office space in New York, NY.

We may in the future be involved in various legal proceedings, claims and litigation that arise in the normal course of business. We accrue for estimated loss contingencies related to legal matters when available information indicates that it is probable a liability has been incurred and we can reasonably estimate the amount of that loss. In many proceedings, however, it is inherently difficult to determine whether any loss is probable or even possible or to estimate the amount of any loss. In addition, even where a loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously recognized loss contingency, it is often not possible to reasonably estimate the size of the possible loss or range of loss or possible additional losses or range of additional losses. Should any of our estimates and assumptions change or prove to be incorrect, it could have a material impact on our results of operations, financial position, and cash flows. As of March 31, 2024 there were no material legal proceedings, claims or litigation.

Our commercial contract arrangements generally include certain provisions requiring us to indemnify customers against liabilities if there is a breach of a customer’s data or if our service infringes a third party’s intellectual property rights. To date, we have not incurred any material costs as a result of such indemnifications.

We have also agreed to indemnify our officers and directors for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request. We maintain director and officer liability insurance coverage that would generally enable us to recover a portion of any future amounts paid. We may also be subject to indemnification obligations by law with respect to the actions of our employees under certain circumstances and in certain jurisdictions.

Table of Contents

Off-Balance Sheet Arrangements

We do not invest in any off-balance sheet vehicles that provide liquidity, capital resources, market or credit risk support, or engage in any activities that expose us to any liability that is not reflected in our condensed consolidated financial statements.

Critical Accounting Policies and Estimates

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Reference is also made to the Company’s consolidated financial statements and notes thereto found in its Annual Report on Form 10-K for the year ended December 31, 2023.

The Company’s accounting policies are essential to understanding and interpreting the financial results reported on the condensed consolidated financial statements. The significant accounting policies used in the preparation of the Company’s consolidated financial statements are summarized in Note 2 to those financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Certain of those policies are considered to be particularly important to the presentation of the Company's financial results because they require management to make difficult, complex or subjective judgments, often as a result of matters that are inherently uncertain.

During the three months ended March 31, 2024, there were no material changes to matters discussed under the heading “Critical Accounting Policies and Estimates” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Recent Accounting Pronouncements

Information regarding recent accounting developments and their impact on our results can be found in Note 2, “Summary of Significant Accounting Policies and Estimates” in the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and in Note 2, “Significant Accounting Policies” in the notes to the condensed consolidated financial statements of this Quarterly Report on Form 10-Q.

Table of Contents

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements regarding our future results of operations and financial position, industry and business trends, stock-based compensation, revenue recognition, business strategy, plans and market growth.

The forward-looking statements in this Quarterly Report and other such statements we publicly make from time-to-time are only predictions. We base these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in Part I, Item 1A, “Risk Factors” of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The forward-looking statements in this Quarterly Report are based upon information available to us as of the date of this Quarterly, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

You should read this Quarterly Report and the risk factors discussed in Part I, Item 1A, “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report on Form 10-Q or any forward-looking statements we may publicly make from time-to-time, whether as a result of any new information, future events or otherwise.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

During the three months ended March 31, 2024, there were no material changes to the information contained in Part II, Item 7A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Based on their evaluation as of March 31, 2024, our management, including our Chief Executive Officer and Chief Financial Officer, have concluded that our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were effective to provide reasonable assurance.

Changes in Internal Control Over Financial Reporting

There were no changes in the Company's internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the first quarter of fiscal year 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We will continue to evaluate each quarter whether there are changes that materially affect our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

The Company has no material pending legal proceedings as of March 31, 2024, for more details see Note 5 “Commitments and Contingencies” in the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

Item 1a. Risk Factors.

In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors discussed under Part I, Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by any forward-looking statements contained in this Quarterly Report. During the three months ended March 31, 2024, there were no material changes to the information contained in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

There were no “Rule 10b5- 1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as the terms are defined in Item 408(a) of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended March 31, 2024 by our directors and Section 16 officers.

Item 6. Exhibits.


	EXHIBIT INDEX	Filed/
Exhibit Number	Exhibit Description	Furnished Herewith

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).	*
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).	*
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.	**
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.	**
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.	*
101.SCH	Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents.	*
104	Cover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101).	*

* Filed herewith.

** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Talkspace, Inc.

Date: May 9, 2024	By:	/s/ Jon Cohen
		Jon Cohen
		Chief Executive Officer

Date: May 9, 2024	By:	/s/ Jennifer Fulk
		Jennifer Fulk
		Chief Financial Officer

Exhibit 31.1

CERTIFICATION

I, Jon Cohen, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Talkspace, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: May 9, 2024	By:	/s/ Jon Cohen
		Jon Cohen
		Chief Executive Officer

Exhibit 31.2

CERTIFICATION

I, Jennifer Fulk, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Talkspace, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: May 9, 2024	By:	/s/ Jennifer Fulk
		Jennifer Fulk
		Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Talkspace, Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2024	By:	/s/ Jon Cohen
		Jon Cohen
		Chief Executive Officer

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2024	By:	/s/ Jennifer Fulk
		Jennifer Fulk
		Chief Financial Officer

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2024	May 06, 2024
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	TALKSPACE, INC.
Entity Central Index Key	0001803901
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		169,684,974
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Securities Act File Number	001-39314
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	84-4636604
Entity Address, Address Line One	622 Third Avenue
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	212
Local Phone Number	284-7206
Document Quarterly Report	true
Document Transition Report	false
Common stock
Document Information [Line Items]
Title of 12(b) Security	Common stock, par value $0.0001 per share
Trading Symbol	TALK
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase common stock
Trading Symbol	TALKW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 120,278	$ 123,908
Accounts receivable, net	11,035	10,174
Other current assets	4,417	5,718
Total current assets	135,730	139,800
Other long-term assets	2,546	2,421
Total assets	138,276	142,221
CURRENT LIABILITIES:
Accounts payable	5,805	6,111
Deferred revenues	2,883	3,069
Accrued expenses and other current liabilities	6,998	12,468
Total current liabilities	15,686	21,648
Warrant liabilities	2,988	1,842
Other long-term liabilities	24	85
Total liabilities	18,698	23,575
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY:
Common stock of $0.0001 par value - Authorized: 1,000,000,000 shares at March, 2024 (unaudited) and December 31, 2023; Issued and outstanding: 169,569,075 and 168,428,856 shares at March 31, 2024 (unaudited) and December 31, 2023, respectively	16	16
Additional paid-in capital	391,412	389,014
Accumulated deficit	(271,850)	(270,384)
Total stockholders' equity	119,578	118,646
Total liabilities and stockholders' equity	$ 138,276	$ 142,221

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	169,569,075	168,428,856
Common stock, shares outstanding	169,569,075	168,428,856

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 45,416	$ 33,336
Cost of revenues	23,685	16,588
Gross profit	21,731	16,748
Operating expenses:
Research and development	3,739	5,353
Clinical operations, net	1,464	1,601
Sales and marketing	13,009	13,469
General and administrative	5,198	5,364
Total operating expenses	23,410	25,787
Operating loss	(1,679)	(9,039)
Financial (income), net	(378)	(424)
Loss before taxes on income	(1,301)	(8,615)
Taxes on income	165	143
Net loss	$ (1,466)	$ (8,758)
Net loss per share:
Earnings Per Share, Basic	$ (0.01)	$ (0.05)
Earnings Per Share, Diluted	$ (0.01)	$ (0.05)
Weighted average number of common shares used in computing basic and diluted net loss per share:
Basic	168,846,946	161,797,781
Diluted	168,846,946	161,797,781

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance, value at Dec. 31, 2022	$ 127,536	$ 16	$ 378,722	$ (251,202)
Beginning balance, shares at Dec. 31, 2022		161,155,030
Exercise of stock options	621		621
Exercise of stock options, share		1,739,265
Restricted stock units vested, net of tax	(65)		(65)
Restricted stock units vested, net of tax, shares		225,050
Stock-based compensation	2,303		2,303
Net Income (Loss)	(8,758)			(8,758)
Ending balance, value at Mar. 31, 2023	121,637	$ 16	381,581	(259,960)
Ending balance, shares at Mar. 31, 2023		163,119,345
Beginning balance, value at Dec. 31, 2023	$ 118,646	$ 16	389,014	(270,384)
Beginning balance, shares at Dec. 31, 2023	168,428,856	168,428,856
Exercise of stock options	$ 741		741
Exercise of stock options, share		605,565
Restricted stock units vested, net of tax	(595)		(595)
Restricted stock units vested, net of tax, shares		534,654
Stock-based compensation	2,252		2,252
Net Income (Loss)	(1,466)			(1,466)
Ending balance, value at Mar. 31, 2024	$ 119,578	$ 16	$ 391,412	$ (271,850)
Ending balance, shares at Mar. 31, 2024	169,569,075	169,569,075

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net Income (Loss)	$ (1,466)	$ (8,758)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	201	306
Stock-based compensation	2,252	2,303
Remeasurement of warrant liabilities	1,146	189
Increase in accounts receivable	(861)	(2,820)
Decrease in other current assets	1,301	559
(Decrease) increase in accounts payable	(306)	1,213
Decrease in deferred revenues	(186)	(232)
Decrease in accrued expenses and other current liabilities	(5,470)	(6,702)
Other	(2)	(95)
Net cash used in operating activities	(3,391)	(14,037)
Cash flows from investing activities:
Purchase of property and equipment	(385)	(9)
Proceeds from sale of property and equipment	0	28
Net cash used in investing activities	(385)	19
Cash flows from financing activities:
Proceeds from exercise of stock options	741	621
Payments for employee taxes withheld related to vested stock-based awards	(595)	(65)
Net cash provided by financing activities	146	556
Net decrease in cash and cash equivalents	(3,630)	(13,462)
Cash and cash equivalents at the beginning of the period	123,908	138,545
Cash and cash equivalents at the end of the period	120,278	125,083
Supplemental cash flow data:
Cash paid during the period for income taxes	$ 15	$ 168

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,466)	$ (8,758)

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2024
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	There were no “Rule 10b5- 1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as the terms are defined in Item 408(a) of Regulation S-K of the Exchange Act) adopted, modified or terminated during the fiscal quarter ended March 31, 2024 by our directors and Section 16 officers.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Organization and Business Operations

3 Months Ended

Mar. 31, 2024

Description Of Organisation And Business Operation [Abstract]

Description of organization and business operations

NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Significant Accounting Policies

NOTE 2. SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

Use of estimates

Recently Issued and Recently Adopted Accounting Pronouncements

Revenue Recognition

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenue Recognition

NOTE 3. REVENUE RECOGNITION

Through its platform, Talkspace serves:

•

Health insurance plans and employee assistance programs (“Payor”) who offer their insured members access to the Company's platform at in-network reimbursement rates,

•

Direct-to-Enterprise customers (“DTE”) who offer their enterprise members access to the Company's platform while their enterprise is under an active contract with Talkspace, and

•

Individual subscribers (“Consumer”) who subscribe directly to the Company's platform.

Payor

DTE

Consumer

The following table presents the Company’s revenues from sales to unaffiliated customers disaggregated by revenue source:


	Three Months Ended March 31,
(in thousands)	2024		2023
Revenues from sales to unaffiliated customers:	Unaudited		Unaudited
Payor	$	28,508	$	14,811
DTE		9,913		8,676
Consumer		6,995		9,849
Total revenue	$	45,416	$	33,336

Accounts Receivable and Allowance for Credit Losses

Deferred Revenue

Fair Value Measurements

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value Measurements

NOTE 4. FAIR VALUE MEASUREMENTS

The following were the inputs utilized in determining the fair value of the Private Placement Warrants as of March 31, 2024 and 2023:


	March 31,
Unaudited	2024	2023
Dividend yield (1)	0%	0%
Expected volatility (2)	56.40%	96.20%
Risk-free interest rate (3)	4.55%	3.75%
Term to warrant expiration (years)	2.22	3.23

(1) No dividends were paid during the three months ended March 31, 2024 and 2023.

(2) The expected volatility is based on the back-solved implied volatility of the Company's public warrants as of the valuation date.

(3) The risk-free interest rate is based on the yield from U.S. Treasury bonds with an equivalent term to the time to maturity of the warrants.

Assets and Liabilities Measured at Fair Value

The Company's assets and liabilities recorded at fair value on a recurring basis as of March 31, 2024 and 2023, have been categorized based upon the fair value hierarchy as follows:


	Fair Value Measurements as of March 31, 2024
	Unaudited
(in thousands)	Level 1		Level 2		Level 3		Total
Assets
Cash	$	446	$	—	$	—	$	446
Cash equivalents
Money market funds		119,832		—		—		119,832
Total cash and cash equivalents	$	120,278	$	—	$	—	$	120,278
Liabilities
Private Placement Warrants		—		—		2,988		2,988
Total Warrant Liabilities	$	—	$	—	$	2,988	$	2,988

	Fair Value Measurements as of December 31, 2023
(in thousands)	Level 1		Level 2		Level 3		Total
Assets
Cash	$	1,078	$	—	$	—	$	1,078
Cash equivalents
Money market funds		122,830		—		—		122,830
Total cash and cash equivalents	$	123,908	$	—	$	—	$	123,908
Liabilities
Private Placement Warrants		—		—		1,842		1,842
Total Warrant Liabilities	$	—	$	—	$	1,842	$	1,842

The following table presents changes in Level 3 liabilities measured at fair value on a recurring basis during the three months ended March 31, 2024 and 2023:


	Level 3 Liabilities
			Unaudited
	For the Three Months Ended March 31, 2024
(in thousands)	Beginning Balance		Change in Fair Value		Ending Balance
Private Placement Warrants	$	1,842	$	1,146	$	2,988

	Level 3 Liabilities
			Unaudited
	For the Three Months Ended March 31, 2023
(in thousands)	Beginning Balance		Change in Fair Value		Ending Balance
Private Placement Warrants	$	939	$	189	$	1,128

Commitments and Contingent Liabilities

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

NOTE 5. COMMITMENTS AND CONTINGENT LIABILITIES

Litigation

Warranties and Indemnification

Capital Stock

3 Months Ended

Mar. 31, 2024

Stockholders' Equity Note [Abstract]

Capital Stock

NOTE 6. CAPITAL STOCK

Share-Based Compensation

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation

NOTE 7. SHARE-BASED COMPENSATION


	Three Months Ended March 31,
	2024		2023
(in thousands)	Unaudited		Unaudited
Research and development	$	635	$	674
Clinical operations, net		51		120
Sales and marketing		449		391
General and administrative		1,117		1,118
Total stock-based compensation expense	$	2,252	$	2,303

Net Loss Per Share

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Net Loss Per Share

NOTE 8. NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented:


	Three Months Ended March 31,
	2024			2023
(in thousands, except share and per share data)	Unaudited			Unaudited
Net loss	$	(1,466	)	$	(8,758	)
Weighted-average shares used to compute net loss per share:
Basic and Diluted		168,846,946			161,797,781
Net loss per share:
Basic and Diluted	$	(0.01	)	$	(0.05	)

Accrued Expenses and Other Current Liabilities

3 Months Ended

Mar. 31, 2024

Accrued Expenses and Other Current Liabilities Abstract

Accrued Expenses and Other Current Liabilities

NOTE 9. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The following table presents the amounts included within accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023:


	March 31, 2024		December 31, 2023
(in thousands)	Unaudited
Employee compensation	$	2,073	$	7,269
User acquisition		1,831		1,525
Professional fees		743		626
Other		2,351		3,048
Accrued expenses and other current liabilities	$	6,998	$	12,468

Variable Interest Entities

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

VARIABLE INTEREST ENTITIES ("VIEs")

NOTE 10. VARIABLE INTEREST ENTITIES ("VIEs")


	March 31, 2024		December 31, 2023
(in thousands)	Unaudited
ASSETS
Cash and cash equivalents	$	603	$	167
Accounts receivable		7,198		4,031
Other assets		9,797		11,493
Total Assets	$	17,598	$	15,691
LIABILITIES
Accrued expenses and other current liabilities		1,691		2,831
Total Liabilities	$	1,691	$	2,831

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The unaudited condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In management’s opinion, the unaudited condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements as of and for the year ended December 31, 2023, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The significant accounting policies applied in the annual consolidated financial statements of the Company as of December 31, 2023, have been applied consistently in these unaudited condensed consolidated financial statements, unless otherwise stated. The Company consolidates all subsidiaries in which it has a controlling financial interest, as well as any VIEs where the Company is deemed to be the primary beneficiary. Intercompany transactions and balances have been eliminated in the preparation of the condensed consolidated financial statements.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the recognition and disclosure of revenue recognition, stock-based compensation awards and the fair value of warrant liabilities. The Company bases its estimates on historical factors, current circumstances and the experience and judgment of management. The Company evaluates its assumptions on an ongoing basis. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based on information available at the time they are made. Estimates, by their nature, are based on judgment and available information, therefore, actual results could be materially different from these estimates.
Recently Issued and Adopted Accounting Pronouncements	Recently Issued and Recently Adopted Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023- 07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-07. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue by Revenue Source

The following table presents the Company’s revenues from sales to unaffiliated customers disaggregated by revenue source:


	Three Months Ended March 31,
(in thousands)	2024		2023
Revenues from sales to unaffiliated customers:	Unaudited		Unaudited
Payor	$	28,508	$	14,811
DTE		9,913		8,676
Consumer		6,995		9,849
Total revenue	$	45,416	$	33,336

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of determining the fair value assumptions of the private placement warrants

The following were the inputs utilized in determining the fair value of the Private Placement Warrants as of March 31, 2024 and 2023:


	March 31,
Unaudited	2024	2023
Dividend yield (1)	0%	0%
Expected volatility (2)	56.40%	96.20%
Risk-free interest rate (3)	4.55%	3.75%
Term to warrant expiration (years)	2.22	3.23

(1) No dividends were paid during the three months ended March 31, 2024 and 2023.

(2) The expected volatility is based on the back-solved implied volatility of the Company's public warrants as of the valuation date.

(3) The risk-free interest rate is based on the yield from U.S. Treasury bonds with an equivalent term to the time to maturity of the warrants.

Summary of Fair Value Measurements

Assets and Liabilities Measured at Fair Value

The Company's assets and liabilities recorded at fair value on a recurring basis as of March 31, 2024 and 2023, have been categorized based upon the fair value hierarchy as follows:


	Fair Value Measurements as of March 31, 2024
	Unaudited
(in thousands)	Level 1		Level 2		Level 3		Total
Assets
Cash	$	446	$	—	$	—	$	446
Cash equivalents
Money market funds		119,832		—		—		119,832
Total cash and cash equivalents	$	120,278	$	—	$	—	$	120,278
Liabilities
Private Placement Warrants		—		—		2,988		2,988
Total Warrant Liabilities	$	—	$	—	$	2,988	$	2,988

	Fair Value Measurements as of December 31, 2023
(in thousands)	Level 1		Level 2		Level 3		Total
Assets
Cash	$	1,078	$	—	$	—	$	1,078
Cash equivalents
Money market funds		122,830		—		—		122,830
Total cash and cash equivalents	$	123,908	$	—	$	—	$	123,908
Liabilities
Private Placement Warrants		—		—		1,842		1,842
Total Warrant Liabilities	$	—	$	—	$	1,842	$	1,842

Summary of warrants

The following table presents changes in Level 3 liabilities measured at fair value on a recurring basis during the three months ended March 31, 2024 and 2023:


	Level 3 Liabilities
			Unaudited
	For the Three Months Ended March 31, 2024
(in thousands)	Beginning Balance		Change in Fair Value		Ending Balance
Private Placement Warrants	$	1,842	$	1,146	$	2,988

	Level 3 Liabilities
			Unaudited
	For the Three Months Ended March 31, 2023
(in thousands)	Beginning Balance		Change in Fair Value		Ending Balance
Private Placement Warrants	$	939	$	189	$	1,128

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Summary of Stock-Based Compensation Expense


	Three Months Ended March 31,
	2024		2023
(in thousands)	Unaudited		Unaudited
Research and development	$	635	$	674
Clinical operations, net		51		120
Sales and marketing		449		391
General and administrative		1,117		1,118
Total stock-based compensation expense	$	2,252	$	2,303

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2024

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented:


	Three Months Ended March 31,
	2024			2023
(in thousands, except share and per share data)	Unaudited			Unaudited
Net loss	$	(1,466	)	$	(8,758	)
Weighted-average shares used to compute net loss per share:
Basic and Diluted		168,846,946			161,797,781
Net loss per share:
Basic and Diluted	$	(0.01	)	$	(0.05	)

Accrued Expenses and Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2024

Accrued Expenses and Other Current Liabilities Abstract

Schedule of accrued expenses and other current liabilities

ccrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023:


	March 31, 2024		December 31, 2023
(in thousands)	Unaudited
Employee compensation	$	2,073	$	7,269
User acquisition		1,831		1,525
Professional fees		743		626
Other		2,351		3,048
Accrued expenses and other current liabilities	$	6,998	$	12,468

Variable Interest Entities (Tables)

3 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Assets and liabilities of the Company's consolidated VIE


	March 31, 2024		December 31, 2023
(in thousands)	Unaudited
ASSETS
Cash and cash equivalents	$	603	$	167
Accounts receivable		7,198		4,031
Other assets		9,797		11,493
Total Assets	$	17,598	$	15,691
LIABILITIES
Accrued expenses and other current liabilities		1,691		2,831
Total Liabilities	$	1,691	$	2,831

Revenue Recognition - Schedule of Disaggregation of Revenue by Revenue Source (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues fom sales to unaffiliated customers:
Total Revenue	$ 45,416	$ 33,336
Payor Revenue
Revenues fom sales to unaffiliated customers:
Total Revenue	28,508	14,811
DTE revenue
Revenues fom sales to unaffiliated customers:
Total Revenue	9,913	8,676
Consumer
Revenues fom sales to unaffiliated customers:
Total Revenue	$ 6,995	$ 9,849

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Accounts receivable, net	$ 11,035	$ 10,174
DTE revenue \| Accounts Receivable [Member]
Disaggregation of Revenue [Line Items]
Accounts receivable, net	8,300	7,800
Payor Revenue
Disaggregation of Revenue [Line Items]
Accounts receivable, net	$ 2,700	$ 2,400

Fair Value Measurements - Additional Information (Detail) - shares

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Dec. 31, 2023

Public Warrant [Member]

Warrants outstanding

21,350,000

Private Placement Warrants

Expected volatility

^[1]

56.40%

96.20%

Warrants outstanding

12,780,000

[1]	The expected volatility is based on the back-solved implied volatility of the Company's public warrants as of the valuation date.

Fair Value Measurements - Schedule of determining the fair value assumptions of the private placement warrants (Details) - Private Placement Warrant [Member]

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Dividend yield

^[1]

0.00%

Expected volatility

^[2]

56.40%

96.20%

Risk-free interest rate

^[3]

4.55%

3.75%

Term to warrant expiration (years)

2 years 2 months 19 days

3 years 2 months 23 days

[1]	No dividends were paid during the three months ended March 31, 2024 and 2023.
[2]	The expected volatility is based on the back-solved implied volatility of the Company's public warrants as of the valuation date.
[3]	The risk-free interest rate is based on the yield from U.S. Treasury bonds with an equivalent term to the time to maturity of the warrants.

Fair Value Measurements - Summary of Fair Value Measurements (Detail) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Inputs, Level 3 [Member] \| Private Placement Warrants
Liabilities:
Total Warrant Liabilities	$ 2,988	$ 1,842	$ 1,128	$ 939
Fair Value, Recurring [Member]
Assets:
Cash	446	1,078
Money market funds	119,832	122,830
Total cash and cash equivalents	120,278	123,908
Liabilities:
Total Warrant Liabilities	2,988	1,842
Fair Value, Recurring [Member] \| Private Placement Warrants
Liabilities:
Total Warrant Liabilities	2,988	1,842
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Cash	446	1,078
Money market funds	119,832	122,830
Total cash and cash equivalents	120,278	123,908
Liabilities:
Total Warrant Liabilities	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Private Placement Warrants
Liabilities:
Total Warrant Liabilities	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Cash	0	0
Money market funds	0	0
Total cash and cash equivalents	0	0
Liabilities:
Total Warrant Liabilities	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Private Placement Warrants
Liabilities:
Total Warrant Liabilities	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets:
Cash	0	0
Money market funds	0	0
Total cash and cash equivalents	0	0
Liabilities:
Total Warrant Liabilities	2,988	1,842
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Private Placement Warrants
Liabilities:
Total Warrant Liabilities	$ 2,988	$ 1,842

Fair Value Measurements - Summary of warrants (Detail) - Private Placement Warrants - Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Class of Warrant or Right [Line Items]
Fair value as of beginning	$ 1,842	$ 939
Change in value	1,146	189
Fair value as of ending	$ 2,988	$ 1,128

Commitments and Contingent Liabilities - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Legal proceedings, claims or litigation	$ 0

Capital Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 31, 2024	Feb. 22, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 11.5		$ 11.5
Common stock, shares authorized	1,000,000,000		1,000,000,000
Common stock, par value	$ 0.0001		$ 0.0001
Preferred stock, shares authorized	100,000,000
Preferred stock, par value	$ 0.0001
Preferred Stock Shares Issued	0		0
Preferred stock, shares outstanding	0		0
Number of shares repurchase program	0
Board of Directors
Class of Stock [Line Items]
Stock repurchase authorized amount		$ 15
Private Placement Warrants
Class of Stock [Line Items]
Warrants and Rights Outstanding	12,780,000		12,780,000
Public Warrants
Class of Stock [Line Items]
Warrants and Rights Outstanding	21,350,000		21,350,000

Share-Based Compensation - Summary of Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	$ 2,252	$ 2,303
Research and Development, net
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	635	674
Clinical Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	51	120
Sales and Marketing
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	449	391
General and Administrative
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expense	$ 1,117	$ 1,118

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Numerator:
Net Income (Loss)	$ (1,466)	$ (8,758)
Denominator:
Weighted average number of common shares used in computing basic net loss per share	168,846,946	161,797,781
Weighted average number of common shares used in computing diluted net loss per share	168,846,946	161,797,781
Net loss per share: Basic	$ (0.01)	$ (0.05)
Net loss per share: Diluted	$ (0.01)	$ (0.05)

Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	9,650,229	11,549,261
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,957,900	14,746,915
Private Placement Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,780,000	12,780,000
Public Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	21,350,000	21,350,000

Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accrued Expense and Other Current Liabilities [Abstract]
Employee compensation	$ 2,073	$ 7,269
User acquisition	1,831	1,525
Professional fees	743	626
Other	2,351	3,048
Accrued expenses and other current liabilities	$ 6,998	$ 12,468

Variable Interest Entities -Additional Information (Details)	3 Months Ended
	Mar. 31, 2024
Variable interest in TPN
Variable Interest Entity [Line Items]
Variable Interest Entity, Financial or Other Support, Reasons	The Company holds a variable interest in Talkspace Provider Network, PA (“TPN”) and eight affiliated professional corporations (“PC entities”). The Company evaluates whether an entity in which it has a variable interest is considered a VIE. VIEs are generally entities that have either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest (i.e., ability to direct the activities of the entity that most significantly impact the entity's economic performance through voting rights and a right to receive the expected residual returns of the entity or an obligation to absorb the expected losses of the entity).

Variable Interest Entities - Summary of assets and liabilities of the Company's consolidated VIE (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 120,278	$ 123,908
Accounts receivable	11,035	10,174
Total assets	138,276	142,221
LIABILITIES
Accrued expenses and other current liabilities	6,998	12,468
Variable Interest Entity [Member]
ASSETS
Cash and cash equivalents	603	167
Accounts receivable	7,198	4,031
Other assets	9,797	11,493
Total assets	17,598	15,691
LIABILITIES
Accrued expenses and other current liabilities	1,691	2,831
Total Liabilities	$ 1,691	$ 2,831